UNSPSC 51172009: Clanobutin

This classification denotes a cholagogue or choleretic agent with the molecular formula C18H18ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W6Y945055S, chemically known as butyric acid, 4-(p-chloro-n-(p-methoxyphenyl)benzamido)- but generally known as clanobutin, which bears US NIH Compound Identifier 35378. European Medicines Agency schedules Clanobutin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06639MIG.

UNSPSC 51172009 Clanobutin is a Commodity code that covers pharmaceutical products used in drug testing and clinical applications. State and local governments procure clanobutin primarily through specimen collection and drug testing services for criminal justice supervision programs, with immunoassay screening and confirmatory testing (LC/MS/MS or GC/MS) driving the operational demand. The buying mix spans county corrections departments, state health and human services agencies, and multistate cooperative purchasing alliances serving diverse public facilities. County community supervision and corrections departments dominate recent activity, driving demand for contracted laboratory services that include specimen collection site operations, interactive voice response systems for randomized testing notifications, and tiered testing methodologies including oral fluid and hair analysis alongside traditional panel screening.

Collin County, Texas leads recent solicitation activity with RFP 2026-327 for Offender Specimen Collection and Drug Testing Services, posted July 9, 2026, with proposals due July 23, 2026. The contract encompasses staffing two collection sites in Plano and McKinney with approximately 25,031 annual tests (5,452 five-panel screens and 18,006 six-panel screens), with an estimated value of $600,000 over two years and three optional one-year renewals. The Texas Health and Human Services Commission issued a parallel Request for Information (RFI HHS0017013) in April 2026 exploring direct-to-manufacturer prescription program capabilities as a market intelligence tool preceding formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in multiple states including Oregon, with responses due March 26, 2026. Collin County requires vendors to hold laboratory certification from SAMHSA, Texas Department of Public Safety, or CAP, while MMCAP mandates cGMP compliance and Drug Supply Chain Security Act certification with relationships to authorized wholesalers. The geographic spread includes Texas and the Upper Midwest, with cooperative purchasing vehicles expanding reach across multiple jurisdictions.